Outcome of Board Meeting held on Wednesday, November 12, 2025, pursuant to Regulations 30, 33 and other applicable Regulations of the SEBI (Listing Obligations and Disclosure Requirements) ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.9 pts less than Nifty Microcap 250 and 0.2 pts less than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The board approved unaudited standalone and consolidated financial results for the half year ended September 30, 2025, along with the auditor's limited review report. Standalone revenue from operations rose to about Rs 6,426 lakhs, up roughly 31% from Rs 4,887 lakhs in H1 FY25. Standalone profit after tax climbed to about Rs 540.5 lakhs from Rs 318.2 lakhs a year ago (around 70% growth), with basic EPS at Rs 4.74. During the half year, the company raised Rs 6,152.71 lakhs via a preferential issue of 25.98 lakh equity shares at Rs 197 each and 20.99 lakh convertible warrants at the same price. Consolidated results also include the newly acquired subsidiary Solar Opto Medic Pvt Ltd (consolidated revenue Rs 6,462 lakhs, PBT Rs 729.6 lakhs). Auditor issued an unqualified review report with no qualifications.
Strong top-line and bottom-line growth combined with a fresh equity infusion suggests the business is expanding, but pending warrant conversion (about Rs 3,102 lakhs yet to be received) could dilute existing shareholders later. Overall, the results are positive for the stock.